Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Non-Hodgkin 4Lymphoma, B-Cell 4Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Recurrence 1Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

Rituximab 4Cladribine 3binimetinib 2Specimen Handling 2CT-P10 2Biopsy 2venetoclax 1tovorafenib 1polatuzumab vedotin 1obinutuzumab 1ibrutinib 1encorafenib 1Vemurafenib 1Spinal Puncture 1Prednisone 1Positron-Emission Tomography 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Hairy Cell × polatuzumab vedotin × Clear all
NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡